

# Fouad Moawad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4564381/publications.pdf>

Version: 2024-02-01

15  
papers

570  
citations

932766

10  
h-index

1199166

12  
g-index

15  
all docs

15  
docs citations

15  
times ranked

517  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia. <i>Gastroenterology</i> , 2018, 154, 1282-1289.e2.	0.6	107
2	Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 603-608.	1.9	101
3	Meta-analysis: the safety and efficacy of dilation in eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 713-720.	1.9	86
4	Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 96-105.	1.9	86
5	Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy. <i>Gastroenterology</i> , 2017, 152, 987-992.	0.6	54
6	Safety of dilation in adults with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2013, 26, 241-245.	0.2	39
7	Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 231-238.	1.9	37
8	Prevalence of eosinophilic esophagitis in a United States military health-care population. <i>Ecological Management and Restoration</i> , 2015, 28, 505-511.	0.2	27
9	Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blind placebo-controlled crossover study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1011-1018.	1.9	11
10	Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 321-326.	1.1	11
11	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 166-186.	1.8	9
12	Letter: distinguishing PPI-responsive oesophageal eosinophilia from eosinophilic esophagitis " still a long way to go; authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1249-1250.	1.9	2
13	Commentary: the proton pump inhibitor test " does it have a role in eosinophilic oesophagitis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 897-898.	1.9	0
14	Editorial: proton pump inhibitor-responsive oesophageal eosinophilia "two different phenotypes? " Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 487-488.	1.9	0
15	Editorial: oesophageal dilation in eosinophilic oesophagitis "can and should, but when and how? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 558-558.	1.9	0